Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Apr 9, 2014 (13 years ago)

Cetirizine Hydrochloride Chewable Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: out of specification results for impurities/degradation testing for N-Oxide

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Cetirizine Hydrochloride Chewable Tablets, 5 mg, 30 count bottle, OTC Manufactured by Sun Pharma, Gujarat, India, NDC 47335-343-83

Affected NDC 47335-0343-83

Compare with the code on your package — it is the most precise check available.

Drug: Cetirizine Category: Allergy & Cold Medication

Recalling firm
Caraco Pharmaceutical Laboratories, Ltd.
NDC code
47335-343-83
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1296-2014 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cetirizine recalls

See all
Class I · High risk

Cetirizine Hydrochloride Tablets USP 5 mg

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

Ongoing Cross-contamination JB Chemicals and Pharmaceuticals Ltd NDC 16571-401-10 D-0732-2026

Other recalls by Caraco Pharmaceutical Laboratories, Ltd.

All 2014 recalls
Class II · Moderate risk

Cephalexin Capsules

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Terminated cGMP deviation Caraco Pharmaceutical Laboratories, Ltd. NDC 62756-294-88 D-1511-2014
Class II · Moderate risk

Cephalexin Capsules

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Terminated cGMP deviation Caraco Pharmaceutical Laboratories, Ltd. NDC 62756-293-88 D-1510-2014
Class II · Moderate risk

Gemcitabine For Injection USP

Lack of Assurance of Sterility: A particle excursion for a different batch of the same product may lead to a lack of sterility assurance.

Terminated Sterility / contamination Caraco Pharmaceutical Laboratories, Ltd. NDC 47335-154-40 D-1407-2014